Skip to content

A clinical study on the involvement of lipid metabolism disorders in the chronic transformation of migraine

A clinical study on the involvement of lipid metabolism disorders in the chronic transformation of migraine

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500098619
Enrollment
Unknown
Registered
2025-03-11
Start date
2024-02-20
Completion date
Unknown
Last updated
2025-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine

Interventions

Sponsors

The First Affiliated Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-60 years old, right-handed; 2. Patients who meet the diagnostic criteria for EM or CM in the 3rd edition of the International Classification of Headache Disorders and are fully qualified to start prophylactic drug therapy; 3. The duration of the patient's headache is more than 1 year; 4. The patient and the patient client understand and abide by the research procedures and methods, voluntarily participate in this experiment, and sign the letter in person signed informed consent; 5. Subjects were able to read, understand, and complete study questionnaires and headache diaries.

Exclusion criteria

Exclusion criteria: 1. Patients with mental illness, suicidal tendency and severe cognitive impairment. 2. Patients who could not cooperate with follow-up, record headache diaries, or refused to enroll. 3. Patients who refuse to sign informed consent. 4. Patients allergic to tobey ester. 5. Patients with urinary calculi.

Design outcomes

Primary

MeasureTime frame
Fatty acids;Oxidized lipid;

Countries

China

Contacts

Public ContactTan Ge

The First Affiliated Hospital of Chongqing Medical University

273346692@qq.com+86 159 2335 8116

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026